XOMA Added to the Russell 2000® and Russell 3000® Indexes
29 Giugno 2020 - 1:30PM
XOMA Corporation (Nasdaq: XOMA) today announced the Company has
been added to the Russell 2000® and Russell 3000® Indexes following
the annual reconstitution, which took effect after the U.S. market
closed on June 26, 2020.
“We expect XOMA’s addition to these Russell indexes will enhance
the Company’s visibility in the investment community and broaden
our shareholder base,” stated Jim Neal, Chief Executive Officer of
XOMA.
The Russell 3000® Index is a market capitalization-weighted
equity index that tracks the performance of the largest 3,000 U.S.
stocks. The Russell 2000® Index measures the performance of
the small-cap segment of the U.S. equity market and is a subset of
the Russell 3000® Index. Inclusion in the Russell 2000® Index
results in automatic inclusion in the appropriate growth and value
style indexes. Russell U.S. Indexes are widely used by
investment managers and institutional investors as the basis for
index funds and as benchmarks for investment strategies.
About XOMA CorporationXOMA has built a
significant portfolio of products that are licensed to and being
developed by other biotechnology and pharmaceutical
companies. The Company’s portfolio of partner-funded programs
spans multiple stages of the drug development process and across
various therapeutic areas. Many of these licenses are the
result of XOMA’s pioneering efforts in the discovery and
development of antibody therapeutics. The Company’s
royalty-aggregator business model includes acquiring additional
licenses to programs with third-party funding. For more
information, visit www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time,
creating additional value for the stockholders, economic outlook,
and potential impact of the COVID-19 pandemic. These
statements are based on assumptions that may not prove accurate,
and actual results could differ materially from those anticipated
due to certain risks inherent in the biotechnology industry,
including those related to the fact that our product candidates
subject to out-license agreements are still being developed, and
our licensees may require substantial funds to continue development
which may not be available; we do not know whether there will be,
or will continue to be, a viable market for the products in which
we have an ownership or royalty interest; if the therapeutic
product candidates to which we have a royalty interest do not
receive regulatory approval, our third-party licensees will not be
able to market them, and the impact to the global economy as a
result of the COVID-19 pandemic. Other potential risks to
XOMA meeting these expectations are described in more detail in
XOMA's most recent filing on Form 10-K and in other SEC
filings. Consider such risks carefully when considering
XOMA's prospects. Any forward-looking statement in this press
release represents XOMA's views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. XOMA disclaims any obligation to
update any forward- looking statement, except as required by
applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development.
Investor contact: Juliane Snowden Oratorium
Group, LLC +1 646-438-9754 jsnowden@oratoriumgroup.com
Media contact: Kathy Vincent KV Consulting
& Management +1 310-403-8951 kathy@kathyvincent.com
Grafico Azioni XOMA (NASDAQ:XOMA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni XOMA (NASDAQ:XOMA)
Storico
Da Apr 2023 a Apr 2024